Royal Bank Of Canada Has Lowered Expectations for United Therapeutics (NASDAQ:UTHR) Stock Price

Key Points

• Royal Bank of Canada lowered United Therapeutics’ price target to $677 from $704 while maintaining an “outperform” rating, implying approximately 28.5% upside from the reported share price.
• United Therapeutics reported quarterly EPS of $7.27, beating expectations of $6.86, but revenue of $783.3 million missed estimates and declined 1.9% year over year.
• Analyst sentiment remains favorable, with 11 buy ratings and two holds, though insider selling—including a $4.9 million sale by CEO Martine Rothblatt—may add some investor caution.

United Therapeutics (NASDAQ:UTHR - Get Free Report) had its price target lowered by stock analysts at Royal Bank Of Canada from $704.00 to $677.00 in a report released on Thursday,Benzinga reports. The firm currently has an "outperform" rating on the biotechnology company's stock. Royal Bank Of Canada's target price would suggest a potential upside of 28.49% from the company's current price.

UTHR has been the subject of a number of other research reports. JPMorgan Chase & Co. boosted their price target on United Therapeutics from $685.00 to $687.00 and gave the company an "overweight" rating in a report on Thursday, July 23rd. Morgan Stanley set a $515.00 price target on United Therapeutics in a research note on Thursday. TD Cowen reiterated a "buy" rating on shares of United Therapeutics in a report on Thursday, May 21st. Wells Fargo & Company upgraded shares of United Therapeutics from an "equal weight" rating to an "overweight" rating and boosted their price target for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Finally, Bank of America dropped their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a "neutral" rating on the stock in a research note on Friday, July 10th. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, United Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $646.00.

United Therapeutics Trading Up 1.5%

United Therapeutics stock traded up $7.90 during mid-day trading on Thursday, hitting $526.91. The company had a trading volume of 601,246 shares, compared to its average volume of 487,208. United Therapeutics has a 12 month low of $292.34 and a 12 month high of $609.35. The company has a market capitalization of $22.37 billion, a PE ratio of 19.48, a price-to-earnings-growth ratio of 1.73 and a beta of 0.59. The stock's 50 day moving average price is $540.37 and its two-hundred day moving average price is $533.71.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping analysts' consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm had revenue of $783.30 million during the quarter, compared to analysts' expectations of $804.65 million. During the same quarter in the previous year, the business earned $6.41 EPS. The company's quarterly revenue was down 1.9% on a year-over-year basis. Equities research analysts anticipate that United Therapeutics will post 26.65 EPS for the current year.

Insider Transactions at United Therapeutics

In other United Therapeutics news, Director Jan Malcolm sold 325 shares of the firm's stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $550.59, for a total value of $178,941.75. Following the completion of the sale, the director owned 450 shares of the company's stock, valued at approximately $247,765.50. This trade represents a 41.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of the company's stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $516.06, for a total transaction of $4,902,570.00. Following the transaction, the chief executive officer owned 324,443 shares in the company, valued at approximately $167,432,054.58. This trade represents a 2.84% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 474,533 shares of company stock valued at $261,703,072. 8.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On United Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Geneos Wealth Management Inc. boosted its position in United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock valued at $45,000 after buying an additional 85 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its stake in United Therapeutics by 18.8% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company's stock valued at $127,000 after acquiring an additional 70 shares during the period. Jump Financial LLC purchased a new stake in shares of United Therapeutics in the 2nd quarter valued at $277,000. Cerity Partners LLC increased its stake in shares of United Therapeutics by 77.3% in the second quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company's stock worth $3,691,000 after acquiring an additional 5,600 shares during the period. Finally, Bank of Nova Scotia increased its stake in shares of United Therapeutics by 6.9% in the second quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company's stock worth $468,000 after acquiring an additional 105 shares during the period. Hedge funds and other institutional investors own 94.08% of the company's stock.

United Therapeutics News Roundup

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics reported second-quarter adjusted earnings of $7.27 per share, exceeding analyst expectations of approximately $6.82–$6.86 and rising from $6.41 a year earlier. The earnings beat supports the stock by highlighting strong profitability and operating leverage. United Therapeutics Q2 Earnings Surpass Estimates
• Positive Sentiment: The company said it submitted regulatory applications for ralinepag and another important pulmonary-disease program. Investors view the pipeline as a potential source of longer-term growth that could diversify United Therapeutics beyond its current pulmonary arterial hypertension products. United Therapeutics Reports Second-Quarter 2026 Results
• Neutral Sentiment: Management’s earnings call balanced near-term Tyvaso-related challenges with progress in ralinepag and other development programs. This creates a mixed outlook: established-product performance remains a concern, but successful pipeline execution could reshape future growth. United Therapeutics Balances Tyvaso Woes With Pipeline Wins
• Negative Sentiment: Second-quarter revenue was $783.3 million, below the roughly $804.7 million consensus estimate and down about 2% year over year. The revenue miss indicates softer demand or product pressure despite the EPS beat, limiting the positive earnings reaction. United Therapeutics Q2 Earnings Beat Estimates, Revenues Miss Mark
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares worth approximately $4.9 million. Although the sale reduced her direct holdings by only 2.84% and may have been routine, insider selling can add modestly to investor caution. United Therapeutics CEO Sells Stock

United Therapeutics Company Profile

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source